5PD - The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling
| Autor: | Vitiello, P.P. 1, Martini, G. 1, Cardone, C. 1, Ciardiello, D. 1, Belli, V. 1, Matrone, N. 1, Troiani, T. 1, Napolitano, S. 1, Sforza, V. 1, Papaccio, G. 2, Desiderio, V. 2, De Falco, V. 1, Giunta, E. 1, Morgillo, F. 1, Diadema, M.R. 1, Vitale, P. 1, Zanaletti, N. 1, Ciardiello, F. 1, Martinelli, E. 1 |
|---|---|
| Zdroj: | In Annals of Oncology September 2017 28 Supplement 5:v2-v2 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|